氨曲南治疗下呼吸道感染的临床疗效观察
【摘要】 目的 观察氨曲南治疗下呼吸道感染的临床疗效和安全性。方法 将346例下呼吸道感染患者随机分为氨曲南2．0 g治疗组173例（A组）和头孢吡肟2．0 g对照组173例（B组），1次/12 h，疗程均为7~14 d。比较两组临床疗效、细菌学改变及不良反应情况。结果 A、B组临床有效率分别为87．28%、88．44%，细菌清除率分别为94．77%、95．78%，二者比较差异无统计学意义（P>0．05）。结论 氨曲南治疗下呼吸道感染安全、有效。
【关键词】氨曲南；头孢吡肟；下呼吸道感染
Clinical observation of aztreonam in the treatment of patients with lower respiratory tract infection
YIN Cheng-fang.Department of Pharmacy,the Affiliated Hospital of Dali College,Yunnan 671000,China
【Abstract】 Objective To evaluate the efficacy and safety of aztreonam in the treatment of patients with lower respiratory tract infection.Methods A total of 346 cases were randomly divided into study group and control group(each group have 173 patients),study group(group A)were treated by aztreonam 2．0 g,control group(group B)were treated by cefepime 2．0 g,q12 h,all patients treated 7~14 days as a course.The clinical efficacy,the bacterial clearance rates and adverse drug reaction of 2 group were compared.Results The clinical efficacy rate of group A and B were 87．28%and 88．44%respectively,the bacterial clearance rates were 94．77%and 95．78%respectively,there were no statistical differences between 2 groups(P>0．05).Conclusion Aztreonam is an effective and safe agent for treatment of patients with lower respiratory tract infection
【Key words】Aztreonam;Cefepime;Lower respiratory tract
下呼吸道感染包括急性支气管炎、慢性支气管炎急性发作、社区获得性肺炎和医院获得性肺炎等疾病。近年来，随着抗菌药物的广泛应用，革兰阴性杆菌感染所占比例明显升高，其耐药菌株亦明显增加[1]。氨曲南(aztreonam)属单环β-内酰胺类抗生素，对革兰阴性杆菌具有...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
